Breaking News

Aptuit, Aegerion in Commercial API Supply Pact

January 9, 2013

Aptuit to supply lomitapide for product launch

Aptuit and Aegerion Pharmaceuticals have signed a long-term supply agreement for commercial quantities of the API lomitapide, Aegerion’s orphan drug targeted for the treatment of a rare disease caused by a genetic disorder.
 
The drug received NDA approval in December of 2012 and is expected to be launched shortly. Aptuit established the chemistry for lomitapide, developed and validated its analytical methods, delivered solid state form control and crystallization R&D, and supplied registration batches of material. Aptuit will continue to supply commercial quantities of lomitapide to Aegerion.
 
Stuart Needleman, president and chief operating officer of Aptuit, said, “Because of the drug’s orphan status and the high unmet medical need of patients, on-time and in-full delivery of the API is crucial. Collaboration across several Aptuit sites in the U.S. and Europe has made this possible. By accessing the vast drug development expertise of our organization, we have been able to accelerate the delivery of materials, methods, solid state chemistry and regulatory documentation and help the client win prompt NDA approval.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016